Onco Actu du 13 novembre 2019

	1. BIOLOGIE
Colorectal Cancer Study Reveals Gut Microbe, Methylation Shifts [Genome Web] From these and other findings, co-senior and co-corresponding author Philippe Sansonetti, a researcher affiliated with the Pasteur Institute and the College of France, and his colleagues suggested that gene methylation may "serve as a marker for CRC and likely for predicting efficacy of prebiotic supplementation in average-risk individuals."
Protein could offer therapeutic target for pancreatic cancer [The Francis Crick Institute] The researchers altered the amount of CD9 in tumour cells in mice and found that when the levels of this protein were reduced, smaller tumours formed. Conversely, increasing levels of CD9 made cancer cells more aggressive and able to form large tumours quickly.
	1.4 BIOLOGIE - TECHNOS, MODÈLES
CRISPR: the movie [Nature] New gene-editing documentary showcases biology’s hottest tool — up to the point when things went awry.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
Former FDA commissioner calls for a full ban on pod-based e-cigarettes [STAT] Gottlieb, however, believes that open-tank vaping systems, such as those sold in dedicated adults-only vape shops, should still be able to stay on the market.
UK teenager needed life support over vaping-linked disease [The Guardian] “There are two important lessons here. The first is always to consider a reaction to e-cigarettes in someone presenting with an atypical respiratory illness. The second is that we consider e-cigarettes as ‘much safer than tobacco’ at our peril,” the paper concludes.
Facing ‘Certain Death,’ Teenager With Vaping Injury Gets Double Lung Transplant [NY Times] The surgery on the 17-year-old was the first transplant reported in the recent nationwide outbreak of vaping-related lung injuries.
Michigan boy, 17, gets double lung transplant after damage from vaping [Reuters] He arrived at Henry Ford on October 3 critically ill and suffering such severe lung damage that he was placed at the top of the list for a transplant, which was performed on October 15, the hospital said.
CDC and Anti-E-Cigarette Researcher Still Clinging to Faint Hope that Traditional E-Cigarettes are Causing Outbreak [The Rest of the Story] I can only conclude that anti-e-cigarette researchers, health groups, and health agencies were actually hoping that the outbreak would be due to traditional e-cigarettes and I honestly think they are disappointed to find out that is not the case. But they are still not willing to concede defeat.
	3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE
Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz [NCI] We now have the evidence to tell us, with great confidence, that those living with and beyond cancer will benefit from being more physically active. We are at a point in the evolution of the field where we can dose exercise precisely, just as we do with drugs, to address several cancer-related health outcomes.
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
Deep Learning Assists in Detecting Malignant Lung Cancers [RSNA] Neural networks may be solution to reducing the number of false positive reads.
	5. TRAITEMENTS
Mount Sinai Researcher’s Examine the Metabolic Effects of an Oral Blood Cancer Drug [Mount Sinai] Recent study found that an effective blood cancer treatment (ruxolitinib) was associated with weight gain, obesity, and increased systolic blood pressure.
	5.10 TRAITEMENTS - ESSAIS
Basic Research Spurs New Wave of Clinical Trials of Therapies for T-Cell Lymphoma [Dana-Farber Cancer Institute] A rare form of non-Hodgkin lymphoma has few standard treatments, but a grant for laboratory and preclinical research has stimulated new focus on clinical trials.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases [Editas] The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells.
Editas and Celgene sub Juno are tackling hottest immunotherapy cells [EndPoints] The new deal will expand the focus of their work to cover a subset of immune cells that have become an increasingly hot target for immunotherapy: gamma-delta cells.
	5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
Kiadis abandons lead PhIII program, shifts focus to natural killer cells [EndPoints] Kiadis acquired CytoSen Therapeutics and its natural killer (NK) technology in April. The Netherlands-based Kiadis had been developing a T cell therapy called ATIR101 that was then in Phase III for blood cancer patients, namely acute myeloid leukemia.
	5.2.3 PHARMA - ÉCONOMIE
Merck shutters French research site in a reorganization aimed at eliminating more than 200 jobs [EndPoints] Merck has also been concentrating more of its research forces in the big global R&D hubs — another common feature in the industry. As such, little research centers like the one in Riom, far to the south of Paris in central France, would be naturally threatened by a global trend like this.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma [Exelixis] Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial.
	6.1 OBSERVATION
Heart disease and cancer risk may be linked [AHA] Using data from the Framingham Heart Study, researchers evaluated data from 12,712 participants (average age 51) without cardiovascular disease or cancer at the start of the study.
	6.7 DMP, BIG DATA & APPLIS
Google’s ‘Project Nightingale’ Secretly Gathers Personal Health Data on Millions of Americans - Time to Refuse Use Of EMR's In Your Healthcare? [Health Care Renewal] I believe invasive healthcare data trafficking projects like this, with potential for massive abuses, provide reasonable justification for patients to REFUSE the use of EHR's in their care.